Jpmorgan Chase & CO Kronos Bio, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 350 shares of KRON stock, worth $339. This represents 0.0% of its overall portfolio holdings.

Number of Shares

350

Previous 350 -0.0%

Holding current value

$339

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$0.75 - $1.49 $878 - $1,744	-1,171 Reduced 76.99%	350 $0
Q3 2023 Nov 14, 2023	SELL	$1.23 - $2.25 $81,729 - $149,505	-66,447 Reduced 97.76%	1,521 $1,000
Q2 2023 Aug 11, 2023	SELL	$1.24 - $1.92 $3.32 Million - $5.13 Million	-2,674,233 Reduced 97.52%	67,968 $116,000
Q1 2023 May 18, 2023	BUY	$1.34 - $2.62 $41,762 - $81,654	31,166 Added 1.15%	2,742,201 $4 Million
Q1 2023 May 11, 2023	BUY	$1.34 - $2.62 $189,533 - $370,580	141,443 Added 5.5%	2,711,035 $3.96 Million
Q4 2022 Feb 13, 2023	BUY	$1.44 - $3.44 $23,040 - $55,040	16,000 Added 0.63%	2,569,592 $4.16 Million
Q3 2022 Nov 14, 2022	SELL	$3.35 - $5.55 $207,452 - $343,689	-61,926 Reduced 2.37%	2,553,592 $8.56 Million
Q2 2022 Aug 11, 2022	BUY	$3.12 - $7.52 $157,469 - $379,541	50,471 Added 1.97%	2,615,518 $9.52 Million
Q1 2022 May 11, 2022	BUY	$6.26 - $14.42 $7.03 Million - $16.2 Million	1,123,528 Added 77.94%	2,565,047 $18.5 Million
Q4 2021 Feb 10, 2022	SELL	$11.35 - $21.18 $524,029 - $977,880	-46,170 Reduced 3.1%	1,441,519 $19.6 Million
Q3 2021 Nov 12, 2021	BUY	$18.17 - $24.7 $27 Million - $36.7 Million	1,487,689 New	1,487,689 $31.2 Million

Others Institutions Holding KRON

# of Institutions

Shares Held

20.7M

Call Options Held

31.4K

Put Options Held

View Full List

About Kronos Bio, Inc.

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $55.1M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

More about KRON

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Kronos Bio, Inc. Transaction History